

2017

Biofunctionalized Capillary Flow Channel Platform Integrated with 3D Nanostructured Matrix to Capture Circulating Tumor Cells

Shashwat Banerjee

Ganesh Khutale

Vrushali Khobragade

See next page for additional authors

Follow this and additional works at: <https://arrow.tudublin.ie/nanolart>

 Part of the [Medicinal-Pharmaceutical Chemistry Commons](#), and the [Oncology Commons](#)

This Article is brought to you for free and open access by the NanoLab at ARROW@TU Dublin. It has been accepted for inclusion in Articles by an authorized administrator of ARROW@TU Dublin. For more information, please contact arrow.admin@tudublin.ie, aisling.coyne@tudublin.ie, gerard.connolly@tudublin.ie.



This work is licensed under a [Creative Commons Attribution-NonCommercial-Share Alike 4.0 License](#)

Authors

Shashwat Banerjee, Ganesh Khutale, Vrushali Khobragade, Narendra Kale, Milind Pore, Govind Chate, Archana Jalota-Badhwar, Manoj Dongare, and Jayant Khandare

Biofunctionalized Capillary Flow Channel Platform Integrated with 3D Nanostructured Matrix to Capture Circulating Tumor Cells

Shashwat S. Banerjee,* Ganesh V. Khutale, Vrushali Khobragade, Narendra R. Kale, Milind Pore, Govind P. Chate, Archana Jalota-Badhwar, Manoj Dongare, and Jayant J. Khandare*

Circulating tumor cells (CTCs) from peripheral blood account genetic information for cancer diagnosis and overall disease monitoring. Analysis of “liquid biopsy” holds immense promise as it may lead to new approaches for cancer treatment. The study reports effective and continuous flow microchannel system for isolating CTCs using transferrin conjugated 3D matrix synthesized by crosslinking polyethylene glycol-Fe₃O₄ nanostructures for rapid and efficient capturing of CTCs. The platform provides option of using multiple microchannel units in series that can influence higher cell-capture efficiency due to increasing cell-substrate contact frequency. CTCs are captured with high efficiency even at low concentration of target cells (~90% at 25 cells per mL blood). Furthermore, the study demonstrates that the cell-capture performance is influenced by topographic interactions between nanostructure based matrix and cancer cells of interest. In addition, this study demonstrates the “proof of concept” using 3D microchannel system having capacity of simultaneously capturing and permanently eliminating CTCs from peripheral blood samples. Further, the study evaluates clinical samples of colon and breast cancer patients for rapid isolation of CTCs. Conclusively, the present platform demonstrates inordinate capacity for cancer cell sorting, biological studies of CTCs, and cancer metastasis, potentially benefiting the real time liquid biopsy and early prognosis of cancer.

1. Introduction

Circulating tumor cells (CTCs) disseminate from the primary tumor and migrate in peripheral blood of cancer patients.^[1–4] CTCs play an important role in metastases and are primarily responsible for the growth of secondary tumors and spread of cancer in distant part of the body.^[5–7] Besides conventional diagnostic approaches (e.g., tumor biopsy, anatomical/molecular imaging, and serum marker detection), detecting CTCs in peripheral blood is of prognostic value to predict disease progression, response to treatment, relapse, and overall survival.^[8–10] However, the detection and characterization of CTCs have been technically challenging due to their extremely low occurrence (10–100 mL⁻¹) among a high number (10⁹ cells mL⁻¹) of hematologic cells in blood.^[7,8] In recent years, a diversity of diagnostic methods have been developed for CTC detection and enrichment that principally include immunomagnetic separation,^[2,11] microfluidic platforms,^[8,12,13] and microfilter devices.^[14]

Microfluidic approaches require precise control over operational parameters and often involve complex designs besides being slow due to lower fluid transfer rates, thus limiting them in time efficiency and high throughput analysis. On the other hand, immunomagnetic methods for separation of CTCs are simple to use but suffer relatively low separation efficiency and require pretreatment of blood to remove hematogenic cells.^[15] Food and Drug Administration-approved CellSearch Technology uses markers with immunomagnetic beads to isolate CTCs. To enhance CTC capturing efficiency and to reduce cost, researchers have been exploring new platforms including microrockets.^[2,5,8,16,17]

Here, we report the use of glass capillary-flow channel functionalized with 3D antibody matrix impinged with magnetic nanoparticles for simultaneous isolation and detection of CTCs from clinical samples. Nanostructure materials such as nanopillars, graphene sheets, and nanoparticles enhance biomolecule

Dr. S. S. Banerjee,^[†] G. V. Khutale,^[††] V. Khobragade, M. Pore, Dr. A. Jalota-Badhwar
Actorius Innovations and Research (AIR)
100 NCL Innovation Park, Pune 411 008, India
E-mail: shashwatbanerjee@mitmimer.com
N. R. Kale, G. P. Chate, Prof. J. J. Khandare
Maharashtra Institute of Pharmacy
MIT Campus
Paud Road, Pune 411 038, India
E-mail: jayant.khandare@mippune.edu.in
M. Dongare
Manik Hospital and Research Center
Aurangabad 431001, India



^[†]Present address: Maharashtra Institute of Medical Education and Research Medical College, Talegaon Dabhade, Pune 410 507, India

^[††]Present address: Nanolab Focas Research Institute, Dublin Institute of Technology, Dublin, 8, Ireland

DOI: 10.1002/admi.201600934




Figure 1. Schematic representation of the configuration and operational mechanism of multi-unit microchannel system for capturing circulating tumor cells (CTCs). a) 3D Fe_3O_4 -GSH-PEG-Tf matrix conjugated microchannel glass substrate with 91 mm of length, 1.55 mm of diameter, and 162 mm^3 volume. b) Cancer patient's blood sample is fed in the first 3D microchannel capillary to capture CTCs. Subsequently, blood with the uncaptured cells from the first microchannel is then fed to the second microchannel capillary and similarly to the third microchannel capillary. Finally, the CTC capturing efficiency is calculated using the set of three cycles. Intermediate outlets between microchannels enable cell capture efficiency estimation of individual microchannels. c) Fe_3O_4 -GSH-PEG-Tf matrix conjugated glass capillary image. d) Pseudo-3D electron microscopy images of glass capillary and e) Fe_3O_4 -GSH-PEG-Tf conjugated glass capillary demonstrating 3D surface on CTC substrate using Zeiss Zen software.

recognition.^[18] Most of these CTC capturing platforms are limited by single unit operations. Therefore, we hypothesized that integrating a flow-channel unit system such as glass capillary with a patterned 3D matrix based on nanostructured materials will offer unique advantages such as (i) better cell–substrate contact frequency leading to enhanced CTC capture due to the 3D matrix and high surface to volume ratio of glass capillary, (ii) opportunity of using multiple units in series for higher cell capture efficiency and sensitivity, (iii) user flexibility to adjust the number of capillary units that best fit his particular assay, and (iv) also the capillaries with different coatings and targeting moieties can be applied simultaneously for isolating CTCs based on specific affinity as well as to sort them as they often exist with many subtypes by multiple isolation steps. Glass-based materials have been widely accepted in applications such as cell fixing substrates and as promising biocompatible materials.^[19,20] However, the glass-based materials suffer from other disadvantages such as low cell affinity. To overcome this, most existing technologies rely on chemical modification to render the inert surfaces bioactive.^[20]

In study we principally employed HCT116 colon cancer cells overexpressing transferrin-receptors (TfRs) to probe the capture efficiency of capillary flow-cell platform. Thus advantages of our platform are: (1) nanoprotusions generated by Poly(ethylene

glycol)-iron oxide (PEG- Fe_3O_4) functionalized “Transferrin-conjugated Nanostructured Matrix on Silane-Functionalized Glass Capillary” (Tf-NMSFGC) increases the topographic interactions between cancer cells and substrate as depicted in **Figure 1**. (2) The dimensions of the platform mediate high density packing of PEG- Fe_3O_4 -Tf on NMSFGC, which results in increased local concentration of Tf, and (3) optimized multi-component 3D matrix with tunable architecture by application of PEG to cross-link Fe_3O_4 nanoparticles. The length of the capillary flow channel was 91 mm while the volume was 162 mm^3 . These aspects of capillary flow channel 3D system synergistically contribute to enhance capture of cancer cells.

2. Results and Discussion

The 3D nanostructured matrix was synthesized through a multistep process (**Figure 2**). First, the cross-linked matrix of PEG- Fe_3O_4 was obtained according to our recent procedure.^[17] Second, the resulting PEG- Fe_3O_4 was functionalized with specific targeting ligand Tf and then chemically immobilized to the amine-functionalized silanated glass through the reactive carboxyl group of the glutathione (GSH) linker using *N*-(3-dimethylaminopropyl)-*N*-ethylcarbodiimide HCl




Figure 2. Synthetic scheme of Tf-NMSFGC microchannel system. a) TEM image of the branched structure where multiple Fe_3O_4 nanoparticles are cross-linked by PEG chains forming a 3D matrix. b) Optical image of a cross-section of Tf-NMSFGC substrate. The average thickness of the matrix (shown by a dotted red circle) estimated from the images was $11 \pm 1 \mu\text{m}$ and few isolated aggregates with thickness $\sim 34 \pm 1 \mu\text{m}$ were also present.

(EDC·HCl) coupling reaction. An amide linkage was formed between the carboxyl group of PEG- Fe_3O_4 and the amine group of silane. Finally, the unreacted components on the glass substrate were removed by a series of washings with Milli-Q water. It was noted that $\approx 2.0 \text{ mg}$ Fe_3O_4 -GSH-PEG-Tf was chemically deposited on the glass substrate. Consequently, a flow-channel system with Fe_3O_4 -GSH-PEG-Tf 3D matrix of $\approx 91 \text{ mm}$ long

chaotic mixing channel ($od = 1.82$ and $id = 1.55 \text{ mm}$) was produced. The amount of amine groups on the silanized glass surface was estimated to be $\approx 16 \text{ nm}^{-2}$. The anchoring of the Fe_3O_4 -GSH-PEG-Tf matrix on the silane-functionalized glass was found to be strong, as the Tf-NMSFGC platform could survive multiple cycles of washings and drying. Figure 2 (inset) shows a typical transmission electron microscopy (TEM)

image of the PEG-Fe₃O₄ matrix, which confirms the cross-linking of the Fe₃O₄ nanoparticles through the PEG chains, thereby leading to 3D nanoscale architecture. The darker parts in the image result from the Fe₃O₄ particles as they are more electron-dense than the PEG chains. The mean size of Fe₃O₄ nanoparticles in the matrix was estimated to be $\approx 24 \pm 8$ nm, which corroborates well with their starting size. It also suggests that the conjugation reaction did not alter the morphology of the particles. Furthermore, the nanosystem was characterized by Fourier Transform Infrared (FTIR) spectroscopy to verify successful conjugation of PEG and Tf to Fe₃O₄-GSH (Figure S1, Supporting Information). The IR spectrum of Fe₃O₄-GSH showed peaks at 1630, 1542, 1390, and 890 cm⁻¹ corresponding to C–N and Fe–O bonds, respectively. The IR spectrum of Fe₃O₄-GSH-PEG and Fe₃O₄-GSH-PEG-Tf showed additional peak at 1262 cm⁻¹ due to C–O stretch and resulted from the presence of PEG. The IR spectrum of Fe₃O₄-GSH-PEG-Tf showed new peak at 1542 cm⁻¹ confirming conjugation of Tf with Fe₃O₄-GSH-PEG.^[17]

The flow-channel substrate was evaluated by analyzing the cross-section of the NMSFGC substrate (Figure 2, inset). The average thickness of the matrix (shown by the dotted red circle) was estimated to be $\approx 11 \pm 1$ μm from the TEM image. A few isolated aggregates with thickness $\approx 34 \pm 1$ μm were also present. The amount of matrix covering the flow-channel surface was estimated to be $\approx 2.0 \pm 0.2$ mg. Furthermore, the matrix was found to cover 90% of the surface when evaluated using optical microscopy and ImageJ software (Figure 3). On the other hand, the density of Tf on the Tf-NMSFGC matrix was estimated to be ≈ 285 mg g⁻¹ by a modified Bradford procedure.

The performance of this integrated flow-channel glass substrate system was evaluated at first using TfR-positive HCT116




Figure 3. Optical microscopy image of microchannel system coated with Fe₃O₄-GSH-PEG-Tf matrix (2.0 mg).

cells. As shown in Figure 4, a 15 min incubation using the Tf-NMSFGC flow-channel system showed excellent cell-capture efficiency of >95% (Figure 5a). Two control experiments based on identical design features (1) without Fe₃O₄-GSH-PEG-Tf matrix on flow-channel device surface and (2) NMSFGC without Tf were also evaluated. As shown in Figure 5a, the flow-channel system without Fe₃O₄-GSH-PEG-Tf matrix and NMSFGC showed significantly less cell attachment of 5% and 52%, respectively. Thus, the (complete) Tf-NMSFGC flow-channel system showed ≈ 19 times and times higher cancer cell-capture efficiency as compared with flow-channel systems without Fe₃O₄-GSH-PEG-Tf matrix and NMSFGC without Tf, respectively. The results clearly confirm that the cancer cell-capture efficiency of the system without Fe₃O₄-GSH-PEG-Tf matrix was significantly less, suggesting that both Fe₃O₄-GSH-PEG matrix and Tf were crucial for enhanced performance. The capture efficiency of Tf-NMSFGC was further investigated with increasing order of cell concentrations of 25, 50, and 100 cells mL⁻¹ (Figure 5b). Tf-NMSFGC was found to




Figure 4. a) Schematic representation of HCT116 cells captured from cell medium on 3D Tf-NMSFGC microchannel system. b,c) Fluorescence images of HCT116 cells captured from cell medium on 3D Tf-NMSFGC microchannel system after 15 min incubation.




Figure 5. a) CTC capture efficiency of Fe_3O_4 -GSH-PEG-Tf coated microchannel system in cell medium ($n = 3$). b) CTC capture efficiency of Fe_3O_4 -GSH-PEG-Tf and Fe_3O_4 -GSH-PEG (control) coated microchannel system in cell medium having different cell concentration ($n = 3$).

capture 96%, 89%, and 88% cells, respectively, demonstrating that the cell-capture efficiency showed a similar trend even at higher cell concentrations. Interestingly, the highest CTC efficiency was achieved with the lower number of cells (i.e., for 25 cells concentration mL^{-1}). This might be due to the optimal cell number and the optimized available surface area in flow-channel substrate. Furthermore, it was found that the captured cells remained intact for ≈ 24 h and could be used for further studies (Figure 6).

To further investigate the influence of Fe_3O_4 -GSH-PEG-Tf matrix on cell capture efficiency, the flow-channel system was functionalized with different amounts of matrix (0.7–2.0 mg per glass capillary) and then evaluated for capturing HCT116 cancer cells. The study showed that the cell capture efficiency increased with increasing amount of 3D matrix (Figure 7). The capture efficiency increased from 48% to 96% when the matrix




Figure 6. Images of HCT116 cells captured on Tf-NMSFGC microchannel system after 24 h. a) 10 \times magnification and b) 20 \times magnification.

amount increased from 0.7 to 2.0 mg. Thus, the flow-channel system with higher matrix amount (2.0 mg) showed two fold increase in capture efficiency for HCT116 cells as compared to the system with lower amount (0.7 mg). This difference further verified the contribution of the matrix in improving cell anchorage due to enhanced topographic interactions between the Fe_3O_4 -GSH-PEG-Tf matrix and the surface of the cancer cells, leading to the enhanced cell capture.

Furthermore, capability of the flow-channel system to capture rare tumor cells was validated using bio-simulated CTC samples. The sample was prepared by spiking Green Fluorescent Protein (GFP) labeled HCT116 cells into whole (human) blood with concentrations of about 25 cells mL^{-1} . For comparison, capture efficiency was also evaluated in lysed blood spiked with similar concentrations of HCT116 cells. After 15 min incubation of the bio-simulated CTC sample in Tf-NMSFGC flow-channel system, HCT116 cells were found to be attached to the Fe_3O_4 -GSH-PEG-Tf matrix as shown in Figure 8a–c. The 3D images of the flow-channel system incubated with spiked blood sample clearly revealed immobilization of the HCT116 cells on Fe_3O_4 -GSH-PEG-Tf matrix, thus confirming the cell capture due to the presence of nanostructure-based matrix (Figure 8d). The CTC capture efficiency in Red Blood Cell (RBC) lysed blood was 92%, and in intact peripheral blood was 88% (Figure 8e), comparable to the capture efficiency in McCoy medium (96%). It can be observed that Tf-NMSFGC flow-channel system could efficiently capture HCT116 cells in all cases. The capture efficiencies were comparable and did not have significant differences regardless of whether the red blood cells were lysed or intact. These results clearly suggest that complex conditions had no significant effects on the cancer cell




Figure 7. Effect of Fe_3O_4 -GSH-PEG-Tf matrix concentration on cell capture efficiency from medium having 25 cells mL^{-1} .




Figure 8. a–c) Bright field and fluorescent images of HCT116 cells captured from spiked blood on 3D Tf-NMSFGC microchannel system after 15 min incubation. d) Pseudo-3D image of CTCs captured on Fe_3O_4 -GSH-PEG-Tf coated capillary. e) CTC capture efficiency of Fe_3O_4 -GSH-PEG-Tf coated capillary in whole blood with RBC lysis, without RBC lysis, and in culture media ($n = 3$).

capturing ability and Tf-NMSFGC flow-channel system can be directly used in whole blood.

After confirming that the Tf-NMSFGC flow-channel system with the matrix can rapidly and efficiently capture tumor cells, we translated the system to study clinical samples from three cancer patients' peripheral blood (including colon and breast cancer patients). As in control, blood was also processed from healthy individuals. Cells were identified as CTCs when stained positive for tumor markers cytokeratin (CK18) and DNA interacting probe (4,6-diamidino-2-phenylindole i.e. DAPI) and negative for leukocyte markers (CD45). The images of CTCs captured from clinical samples with our method from 0.1 mL of blood are shown in **Figure 9**. As shown in the image, CTCs exhibited strong CK staining and DAPI staining confirming intact nuclei in the captured cells. Conversely, no CTC was found in any healthy samples, suggesting that the Tf-NMSFGC flow-channel system can be successfully applied to real patient blood samples. We anticipate the capture of CTCs from cancer patients having anti-epithelial cell adhesion molecules (EpCAM). Further study in this direction with greater numbers of clinical samples is currently in progress. Our system exhibited excellent capacity in capturing CTCs as it offers flexibility of using 3D flow-channel system units in series for cancer cell capture, which is otherwise not easy to be captured from one cycle. A continuous microflow-system in controlling the feed and output using patient's sample is currently being designed and evaluated.

3. Conclusions

We developed a new-generation flow-channel system by synergistically incorporating Fe_3O_4 -GSH-PEG-Tf nanostructured 3D matrix by chemical conjugation. This unique flow-channel system combines simple flow-channel system with a 3D nanostructured matrix to produce a synergistic effect of enhanced cell–substrate contact frequency as well as affinity. The resulting flow-channel system exhibited efficient and rapid (within 15 min) CTC-capturing ability in both cell medium and in spiked blood samples. Furthermore, the system was successfully employed for detecting cancer patient's clinical peripheral blood samples, endorsing their clinical potential in CTC studies. We envision that the novel flow-channel will open new opportunities for early diagnosis of cancer metastasis as well as recovery of other rare cells, proteins, DNA, and from biological specimens.

4. Experimental Section

Reagents: Bis-NHS-PEG, EDC-HCl, *N,N*-diisopropyl ethylamine (DIPEA), ferric chloride tetrahydrate, ferrous chloride hexahydrate, and transferrin (Tf) were purchased from Sigma-Aldrich (St. Louis, MO). GSH and *N*-hydroxysuccinimide (NHS) were procured from Sigma-Aldrich Chemical Co. (Germany). Milli-Q water, obtained from a Millipore water purification system (Merck Millipore, India), was used throughout the study. All chemicals were of the analytical grade and were used without further purification.




Figure 9. Bright field and fluorescent images of CTCs captured from blood samples of a colon cancer patient. a) Immunocytochemistry method based on Fluorescein Isothiocyanate-labeled anti-cytokeratin (green), PE-labeled anti-CD45 (red), and DAPI (blue) nuclear staining was applied to identify and enumerate CTCs on Fe_3O_4 -GSH-PEG-Tf coated capillary. The fluorescence images were acquired in 3D capillary at different planar positions with highest intensity. b) Bright field and fluorescent merged images of CTCs captured on 3D microchannel system in series.

Synthesis of Fe_3O_4 -GSH Conjugate: Fe_3O_4 nanoparticles were synthesized by co-precipitation of Fe^{2+} and Fe^{3+} ions using ammonia base followed by hydrothermal ripening of nanoparticles.^[21] For typical nanoparticle functionalization reaction, 500 mg of Fe_3O_4 was dispersed in 15 mL Milli-Q water and 5 mL methanol by sonication for 15 min. 400 mg of GSH was dissolved in Milli-Q water and mixed with Fe_3O_4 solution. The mixture was then re-sonicated for 2 h. Fe_3O_4 -GSH was then isolated by magnetic separation, washed with repeated cycles of excess Milli-Q water, and dried under vacuum.

Synthesis of Fe_3O_4 -GSH-PEG Conjugate: 120 mg of bis[2-(N-succinimidyl-succinylamino)ethyl]polyethylene glycol (Bis-NHS-PEG; 3 kDa) was dissolved in 6 mL of Milli-Q water and was allowed to react with 30 mg of Fe_3O_4 -GSH in the presence of 100 μL of 1000 ppm DIPEA at a final solution pH of 7.8. The reaction mixture was continuously stirred at room temperature for 24 h. Fe_3O_4 -GSH-PEG was then isolated by magnetic separation, washed with repeated cycles of excess Milli-Q water, and dried under vacuum.

Synthesis of Tf-PEG-GSH- Fe_3O_4 : 40 mg of PEG-GSH- Fe_3O_4 was first gently stirred in the presence of 200×10^{-3} M EDC-HCl and 200×10^{-3} M NHS at pH ~ 6.0 for 15 min to activate the carboxyl groups at room temperature. Next, 10 mg of Tf was incubated with activated

PEG-GSH- Fe_3O_4 for 4 h at room temperature, then washed with Milli-Q water, and finally dried.

Functionalization of Glass Capillary: Commercially available glass capillaries were activated in hot (80–90 °C) piranha solution (H_2O_2 (30%): H_2SO_4) (1:3) for 2 h. The treated glass capillaries were then rinsed thoroughly with Milli-Q water and dried under vacuum at room temperature. Silanization of the glass capillary surface was carried out by treating the glass with (3-aminopropyl) triethoxysilane in toluene (3% solution) at room temperature for 24 h. The glass substrates were rinsed with toluene and Milli-Q water, respectively, and the density of the amine groups on the silanized glass surface was estimated by a colorimetric assay reported by Noel et al.^[22] Five different silanized substrates were measured to estimate the average density of amine groups on the silanized surfaces.

Anchoring Fe_3O_4 -GSH-PEG-Tf Matrix on Silane-Functionalized Glass Capillary: First, the carboxyl group in the GSH linker of Fe_3O_4 -GSH-PEG-Tf (10 mg) was activated in 3 mL solution of 200×10^{-3} M EDC-HCl and 200×10^{-3} M NHS with gentle shaking for 15 min. 10 μL of Fe_3O_4 -GSH-PEG-Tf solution was passed through the inert part of silanized glass capillary and the capillary was rolled for 2 min for uniform coating. This step was repeated twice and finally the film was

dried under vacuum at room temperature. The coated glass capillary (NMSFGC) was then repeatedly washed with Milli-Q water to remove any noncovalently attached material and again re-dried under vacuum at room temperature.

Cell Culture and Patients: HCT116 cells (ATCC) were cultured in McCoy's cell culture medium (Invitrogen) supplemented with 10% fetal calf serum (Invitrogen), 100 units penicillin (Invitrogen), and 100 $\mu\text{g mL}^{-1}$ streptomycin (Invitrogen) in 25 cm^2 flask. After incubation for 4 d at 37 °C and 5% CO_2 , cells were trypsinized, stained with 1 \times Trypan blue, and counted using Neubauer chamber. Blood from healthy volunteer was obtained by strictly following protocols and guidelines of the ethics committee. All cancer patient samples included in this study were collected at Manik Hospital and Research Center, Aurangabad, India with their informed consent. The Manik Hospital and Research Center ethics committee approved the study and consent forms. The conducted study strictly adhered to the approved protocols and the guidelines of the ethics committee.

Capture of Cancer Cells in McCoy Medium: Preliminary studies revealed that the optimal volume of the glass capillary to hold cell medium was 100 μL . This optimal condition was employed in further studies for CTC capture and isolation from McCoy medium. 100 μL of McCoy medium containing low concentration of HCT116 cells (25 cells mL^{-1}) was introduced in Tf-NMSFGC using micropipette and then rolled inside the capillary for 5 min in order to initiate the interaction between the cells and Fe_3O_4 -GSH-PEG-Tf. After 5 min the sample was collected from the capillary using micropipette and transferred to another Tf-NMSFGC and again rolled inside it for another 5 min. This procedure was repeated one more time. The sample was then collected in 96-well plates using micropipette. The capillaries were rinsed with PBS at least three times in order to remove unattached cells. The number of uncaptured cells was counted using the Zeiss Axio Observer A1 fluorescence microscope. Also, the capture efficiency in medium with different cell concentrations of ≈ 25 , 50, and 100 cells $100 \mu\text{L}^{-1}$ was also evaluated.

Capture of Cancer Cells from Cancer Cell-Spiked Blood Samples: 25 dual fluorescent HCT116 cells were spiked in 100 μL of blood from healthy person. Then the blood was lysed using RBC lysis buffer using 1:3 blood:RBC lysis buffer proportion. The sample was incubated at room temperature on rotator at 50 rpm for 5 min, followed by centrifugation at 2000 rpm for 3 min. The supernatant was discarded and pellet was re-suspended in 100 μL PBS. This PBS was inserted in Tf-NMSFGC and rolled inside the capillary for 5 min in order to initiate the artificial CTC sample and Fe_3O_4 -GSH-PEG-Tf interaction. After 5 min the sample was collected from the capillary using micropipette and transferred to another Tf-NMSFGC and rolled inside it for another 5 min. This procedure was repeated one more time. The sample was then collected in 96-well plates using micropipette followed by rinsing of the capillaries with PBS at least three times. The number of uncaptured cells was counted using the Zeiss Axio Observer A1 fluorescence microscope.

Capture of CTC Cells from Clinical Colon Cancer Patient Sample: Peripheral blood obtained from clinically advanced cancer patients (including colon and breast cancer patients) in the age group of 45–60 years was used for the experiment. 1 mL of the blood was lysed in 3 mL RBC lysis buffer at room temperature for 15 min on rotator at 50 rpm. The sample was centrifuged at 2000 rpm for 15 min at room temperature. The supernatant was discarded and pellet was resuspended in 500 μL PBS. This was followed by fixation of the sample by incubating with 4% paraformaldehyde (500 μL) for 10 min on rotator at 50 rpm. The sample was then centrifuged at 2000 rpm for 15 min at room temperature. The supernatant was discarded and pellet was resuspended in 300 μL PBS. Finally, the sample was stained with anicytokeratin18 (Abcam) and anti CD45 antibodies (Santa Cruz Biotechnology) for 1 h at room temperature and DAPI (0.5 mg mL^{-1}) for 10 min at room temperature and visualized in 96-well plates under the fluorescence microscope (Zeiss Axio Observer A1 fluorescence microscope). After confirming that the stained/tested blood fraction contains cancer cell, the blood was inserted in the Tf-NMSFGC flow channel and rolled inside the capillary for 5 min in order to initiate the blood and Fe_3O_4 -GSH-PEG-Tf interaction. After 5 min the sample

was collected from the capillary using micropipette and transferred to another Tf-NMSFGC and again rolled inside it for another 5 min. This procedure was repeated one more time. The blood sample was then collected in 96-well plates using micropipette. The capillaries were rinsed with PBS at least three times to get rid of unattached cells. The number of uncaptured cells was counted using the fluorescence microscope.

Characterization: TEM analysis was performed using a Philips (CM 200) TEM machine set at an accelerating voltage of 200 kV. Samples for TEM were prepared by placing a drop of the Fe_3O_4 -GSH-PEG-Tf suspension in deionized water on a Formvar-covered copper grid and then evaporating the water at room temperature. Conjugation of protein (Tf) to Fe_3O_4 -GSH-PEG was confirmed by a modified Bradford assay. Fluorescence imaging and counting of cells were performed using Zeiss Axio Observer A1 microscope (Carl Zeiss, Jena, Germany).

Supporting Information

Supporting Information is available from the Wiley Online Library or from the author.

Acknowledgements

The authors would like to acknowledge the financial support from the Biotechnology Ignition Grant (BIG), Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT). J.J.K. acknowledges nanobiotechnology research grant from the Department of Biotechnology and funds for improvement of science and technology infrastructure from the Department of Science and Technology (FIST-DST).

Received: September 29, 2016

Revised: November 15, 2016

Published online: January 18, 2017

- [1] K. Pantel, R. H. Brakenhoff, B. Brandt, *Nat. Rev. Cancer* **2008**, *8*, 329.
- [2] S. S. Banerjee, A. Jalota-Badhwar, S. D. Satavalekar, S. G. Bhansali, N. D. Aher, R. R. Mascarenhas, D. Paul, S. Sharma, J. J. Khandare, *Adv. Healthcare Mater.* **2013**, *2*, 800.
- [3] J. Kaiser, *Science* **2010**, *327*, 1074.
- [4] S. S. Banerjee, A. Jalota-Badhwar, K. R. Zope, K. J. Todkar, R. R. Mascarenhas, G. P. Chate, G. V. Khutale, A. Bharde, M. Calderon, J. J. Khandare, *Nanoscale* **2015**, *7*, 8684.
- [5] K. Pantel, R. H. Brakenhoff, *Nat. Rev. Cancer* **2004**, *4*, 448.
- [6] A. H. Kuo, M. F. Clarke, *Nat. Biotechnol.* **2013**, *31*, 504.
- [7] C. A. Klein, *Science* **2008**, *321*, 1785.
- [8] S. Nagrath, L. V. Sequist, S. Maheswaran, D. W. Bell, D. Irimia, L. Ulkus, M. R. Smith, E. L. Kwak, S. Digumarthy, A. Muzikansky, P. Ryan, U. J. Balis, R. G. Tompkins, D. A. Haber, M. Toner, *Nature* **2007**, *450*, 1235.
- [9] E. I. Galanza, E. V. Shashkov, T. Kelly, J. W. Kim, L. Yang, V. P. Zharov, *Nat. Nanotechnol.* **2009**, *4*, 855.
- [10] Q. Shen, L. Xu, L. Zhao, D. Wu, Y. Fan, Y. Zhou, W. H. OuYang, X. Xu, Z. Zhang, M. Song, T. Lee, M. A. Garcia, B. Xiong, S. Hou, H. R. Tseng, X. Fang, *Adv. Mater.* **2013**, *25*, 2368.
- [11] A. H. Talasaz, A. A. Powell, D. E. Huber, J. G. Berbee, K. H. Roh, W. Yu, W. Xiao, M. M. Davis, R. F. Pease, M. N. Mindrinos, S. S. Jeffrey, R. W. Davis, *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 3970.
- [12] A. Adams, P. I. Okagbare, J. Feng, M. L. Hupert, D. Patterson, J. Gttert, R. L. McCarley, D. Nikitopoulos, M. C. Murphy, S. A. Soper, *J. Am. Chem. Soc.* **2008**, *130*, 8633.
- [13] S. Wang, K. Liu, J. Liu, Z. T. F. Yu, X. Xu, L. Zhao, T. Lee, E. K. Lee, J. Reiss, Y. K. Lee, L. W. K. Chung, J. Huang, M. Rettig, D. Seligson,

- K. N. Duraiswamy, C. K. F. Shen, H. R. Tseng, *Angew. Chem. Int. Ed.* **2011**, *50*, 3084.
- [14] S. Zheng, H. Lin, J. Q. Liu, M. Balic, R. Datar, R. J. Cote, Y. C. Tai, *J. Chromatogr. A* **2007**, *1162*, 154.
- [15] Z. A. Nima, M. Mahmood, Y. Xu, T. Mustafa, F. Watanabe, D. A. Nedosekin, M. A. Juratli, T. Fahmi, E. I. Galanzha, J. P. Nolan, A. G. Basnakian, V. P. Zharov, A. S. Biris, *Sci. Rep.* **2014**, *4*, 4752.
- [16] G. Vona, A. Sabile, M. Louha, V. Sitruk, S. Romana, K. Schutze, F. Capron, D. Franco, M. Pazzagli, M. Vekemans, B. Lacour, C. Brechot, P. Paterlini-Brechot, *Am. J. Pathol.* **2000**, *156*, 57.
- [17] S. S. Banerjee, D. Paul, S. G. Bhansali, N. D. Aher, A. Jalota-Badhwar, J. Khandare, *Small* **2012**, *8*, 1657.
- [18] E. Reátegui, N. Aceto, E. J. Lim, J. P. Sullivan, A. E. Jensen, M. Zeinali, J. M. Martel, A. J. Aranyosi, W. Li, S. Castleberry, A. Bardia, L. V. Sequist, D. A. Haber, S. Maheswaran, P. T. Hammond, M. Toner, S. L. Stott, *Adv. Mater.* **2015**, *27*, 1593.
- [19] J. S. Miller, K. R. Stevens, M. T. Yang, B. M. Baker, D. H. T. Nguyen, D. M. Cohen, E. Toro, A. A. Chen, P. A. Galie, X. Yu, R. Chaturvedi, S. N. Bhatia, C. S. Chen, *Nat. Mater.* **2012**, *11*, 768.
- [20] G. Yang, Y. Cao, J. Fan, H. Liu, F. Zhang, P. Zhang, C. Huang, L. Jiang, S. Wang, *Angew. Chem., Int. Ed.* **2014**, *53*, 2915.
- [21] S. S. Banerjee, D. H. Chen, *Chem. Mater.* **2007**, *19*, 6345.
- [22] S. Noel, B. Liberelle, L. Robitaille, G. De Crescenzo, *Bioconjugate Chem.* **2011**, *22*, 1690.